Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa

Abstract

Discussing the importance of patient advocacy and the advancement of systemic therapies for the treatment of liver cancer, we catch up with Hepatic Oncology's latest editorial board member Ghassan Abou-Alfa.

Keywords: advocacy; cabozantinib; hepatocellular carcinoma; systemic therapies; tyrosine kinase inhibitors.